HROW|Harrow Inc|Price:33.910|Chg%:-2.44

More Details of Harrow Inc Company

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Harrow Inc Info



Ticker SymbolHROW

Company nameHarrow Inc

IPO dateFeb 08, 2013

CEOMullery (Frank)

Number of employees382

Security typeOrdinary Share

Fiscal year-endFeb 08

Address1A Burton Hills Blvd

CityNASHVILLE

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code37215

Phone16157334731

Websitehttps://www.harrow.com/

Ticker SymbolHROW

IPO dateFeb 08, 2013

CEOMullery (Frank)

Company Executives of Harrow Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+3.35%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+4.11%

Mr. Perry J. Sternberg

Lead Independent Director

--

Dr. Adrienne L. Graves, Ph.D.

Independent Director

--

Mrs. Lauren P. Silvernail

Independent Director

--

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

--

Mr. Randall E. Pollard, CPA

Chief Accounting Officer

--

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

--

Name

Name/Position

Position

Shareholding

Change

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+3.35%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+4.11%

Mr. Perry J. Sternberg

Lead Independent Director

--

Dr. Adrienne L. Graves, Ph.D.

Independent Director

--

Mrs. Lauren P. Silvernail

Independent Director

--

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

--

Revenue Breakdown

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

Shareholding Stats

Updated: Thu, Feb 19

Shareholders

Shareholder Types

Shareholders

Proportion

Opaleye Management Inc.

9.89%

Baum (Mark L)

8.02%

BlackRock Institutional Trust Company, N.A.

6.03%

The Vanguard Group, Inc.

5.14%

Kaufman (Daniel)

5.04%

Other

65.88%

Shareholders

Proportion

Opaleye Management Inc.

9.89%

Baum (Mark L)

8.02%

BlackRock Institutional Trust Company, N.A.

6.03%

The Vanguard Group, Inc.

5.14%

Kaufman (Daniel)

5.04%

Other

65.88%

Shareholder Types

Shareholders

Proportion

Investment Advisor

21.50%

Investment Advisor/Hedge Fund

19.21%

Individual Investor

16.50%

Hedge Fund

15.57%

Research Firm

2.51%

Pension Fund

1.07%

Bank and Trust

0.39%

Private Equity

0.05%

Insurance Company

0.03%

Other

23.18%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

387

21.85M

59.00%

-2.41M

2025Q3

360

21.75M

58.77%

-3.27M

2025Q2

345

26.63M

72.57%

-2.99M

2025Q1

354

25.78M

70.87%

-4.22M

2024Q4

350

26.13M

73.38%

-4.49M

2024Q3

325

25.90M

72.95%

-2.80M

2024Q2

296

24.70M

70.19%

-6.36M

2024Q1

284

26.34M

74.95%

-7.20M

2023Q4

279

28.26M

80.94%

-4.94M

2023Q3

275

28.51M

81.73%

-152.59K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Opaleye Management Inc.

3.90M

10.54%

--

Sep 30, 2025

Baum (Mark L)

2.99M

8.06%

+100.01K

+3.47%

Dec 12, 2025

BlackRock Institutional Trust Company, N.A.

2.23M

6.02%

-24.19K

-1.07%

Sep 30, 2025

The Vanguard Group, Inc.

1.86M

5.03%

+131.00

+0.01%

Sep 30, 2025

Kaufman (Daniel)

1.68M

4.55%

-222.91K

-11.69%

Aug 12, 2024

Private Capital Management

1.86M

5.01%

-89.70K

-4.61%

Sep 30, 2025

Luxor Capital Group, L.P.

307.34K

0.83%

+307.34K

--

Sep 30, 2025

Boll (Andrew R)

811.18K

2.19%

+33.34K

+4.29%

Dec 12, 2025

Geode Capital Management, L.L.C.

775.64K

2.09%

-35.16K

-4.34%

Sep 30, 2025

State Street Investment Management (US)

794.28K

2.14%

+21.18K

+2.74%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

State Street SPDR S&P Pharmaceuticals ETF

2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

0.68%

First Trust Small Cap Growth AlphaDEX Fund

0.63%

iShares U.S. Pharmaceuticals ETF

0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

0.37%

iShares Micro-Cap ETF

0.23%

First Trust Small Cap Core Alphadex Fund

0.2%

First Trust Multicap Growth Alphadex Fund

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Avantis US Small Cap Equity ETF

0.08%

State Street SPDR S&P Pharmaceuticals ETF

Proportion2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

Proportion0.68%

First Trust Small Cap Growth AlphaDEX Fund

Proportion0.63%

iShares U.S. Pharmaceuticals ETF

Proportion0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion0.37%

iShares Micro-Cap ETF

Proportion0.23%

First Trust Small Cap Core Alphadex Fund

Proportion0.2%

First Trust Multicap Growth Alphadex Fund

Proportion0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Proportion0.08%

Avantis US Small Cap Equity ETF

Proportion0.08%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data